Translink Project

Menu

Skip to content
  • Home
  • About Translink
    • Organization
      • Coordination
      • Administrative management
      • Executive Board
      • Project Board
      • Project management office
      • External Advisory Boards
      • Dissemination and training management
    • Concept and Objectives
    • Translink Work Plan
    • Heart valve pathology - the TransLink target
    • Clinical Trials
    • For patients
    • Training Course 2015
    • Training Course 2017
    • Conference 2016
  • Ethics
  • News
  • Partners
    • University of Manitoba (UM)
    • AZIENDA OSPEDALIERA DI PADOVA (AOP)
    • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    • CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES (CHU)
    • ICS BELLVITGE UNIVERSITY HOSPITAL (HUB)
    • ICS-VALL D’HEBRON UNIVERSITY HOSPITAL (HUVB)
    • FUNDACIÓ INSTITUT D’INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL)
    • UNIVERSITY COLLEGE LONDON (UCL)
    • TELAVIV UNIVERSITY (TAU)
    • GOETEBORGS UNIVERSITET (UGOT)
    • AVANTEA (AVT)
    • INKEMIA IUCT GROUP (IUCT)
    • MIND THE BYTE (MtB)
    • UNIVERSITA DEGLI STUDI DI PADOVA (UNIDP)
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (UCAL)
  • Scientific Publications
  • Final Conference 2018
  • Contact

TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery). BHV clinical outcome suffers from late dysfunctions restricting their application to older recipients. Based on a retrospective (already computerised) and prospective cohort of approximately 3,000 BHV recipients and control patients from 3 large EU cardiac surgery groups, TRANSLINK aims primarily to establish the possible role of recipients' immune response (IR) against BHV as a major cause to mid- to-long term clinical dysfunction. Download our leaflet for more information about TransLink project

EU project


Project financed by the European Union Seventh Framework Programme (FP7/2007-2013) under the Grant Agreement 603049.

Latest news

  • Widely covered Final TransLink conference
  • TransLink SMEs on the move
  • Six new experts in Genome editing formed by TransLink project
  • Cardiac pathologies: therapeutic innovation between surgery, chemistry and biotechnology
  • TransLink member achieve an ERC starting grant.

Twitter feeds

© TRANSLINK PROJECT | PADOVA - ITALY 2014 | AOP | ALL RIGHTS RESERVED - Site by Mind the Byte
This is a website recovered by the free version of the Wayback Downloader.